Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected

Luis M Molinos-Albert, Jorge Carrillo, Marta Curriu

  • 1IrsiCaixa-HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, UAB, Badalona, 08916 Barcelona, Catalonia, Spain. jblanco@irsicaixa.es.

Retrovirology
|June 10, 2014
PubMed
Abstract

Insights

Broadly neutralizing antibodies targeting the MPER region of HIV-1 gp41 are present in most infected individuals. However, their neutralizing capacity varies significantly, indicating a need for refined immunogen design for effective vaccine development.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • The Membrane Proximal External Region (MPER) of HIV-1 gp41 is a key target for broadly neutralizing antibodies.
  • The hydrophobic nature of the MPER epitope may hinder antibody elicitation in infected individuals.

Purpose of the Study:

  • To quantify and characterize anti-MPER antibodies in HIV-1 infected individuals.
  • To assess the neutralizing capacity of anti-MPER antibodies against MPER-grafted viruses.

Main Methods:

  • ELISA and flow cytometry using gp41-derived miniproteins on 293T cells.
  • Analysis of longitudinal plasma samples from 35 HIV-1 infected individuals.
  • Assay of MPER recognition and neutralization using HIV-2 viruses with HIV-1 MPER sequences.

Main Results:

  • Anti-MPER antibodies were detected in most individuals and were stable over time.
  • Antibody response magnitude correlated with the overall anti-HIV-1 envelope response.
  • Significant functional heterogeneity was observed, with antibody titers not correlating with neutralization capacity.

Conclusions:

  • Anti-MPER antibodies are common in HIV-1 infected individuals within the broader anti-Env response.
  • The heterogeneous neutralizing capacity suggests current immunogens may elicit non-neutralizing responses.
  • Refined immunogen strategies are necessary to elicit potent neutralizing anti-MPER antibodies for vaccine development.